22179-78-8

Basic information

• Product Name: 4-FLUOROBENZAMIDOXIME
• Synonyms: BUTTPARK 52\12-13;4-FLUORO-N-HYDROXY-BENZAMIDINE;4-FLUORO-BENZAMIDE OXIME;4-FLUOROBENZAMIDOXIME;Bolddenone;4-fluoro-N-[(1E)-(hydroxyiMino)Methyl]benzaMide;N-Hydroxy-4-fluorobenzamidine;(E)-4-fluoro-N'-hydroxybenzimidamide
• CAS NO: 22179-78-8
• Molecular Formula: C₇H₇FN₂O
• Molecular Weight: 154.14
• Product Categories: pharmacetical
• Mol File: 22179-78-8.mol
• Article Data: 74

Chemical Properties

• Melting Point: 92-95 °C(lit.)
• Boiling Point: 299.8 °C at 760 mmHg
• Flash Point: 135.1 °C
• Appearance: White/Solid
• Density: 1.3 g/cm³
• PKA: 6.80±0.69(Predicted)
• CAS DataBase Reference: 4-FLUOROBENZAMIDOXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUOROBENZAMIDOXIME(22179-78-8)
• EPA Substance Registry System: 4-FLUOROBENZAMIDOXIME(22179-78-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 22179-78-8(Hazardous Substances Data)

Usage

Physical Form

Solid

Uses

4-Fluorobenzamidoxime is used as building block for pharmaceutical, agrochemical, advanced materials etc.

Upstream product

• 1194-02-1 4-fluorobenzonitrile 
• 459-23-4 4-fluorobenzaldoxime 
• 459-57-4 4-fluorobenzaldehyde 
• 460-00-4 1-Bromo-4-fluorobenzene 

Downstream Products

• 75907-91-4 O-(4,4-Dinitropentanoyl)-4-fluorobenzamidoxime 
• 719274-56-3 methyl 4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]bicyclo[2.2.2]octane-1-carboxylate 
• 851882-60-5 (R)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidine-1-carboxylic acid tert-butyl ester 
• 915874-63-4 3-(4-fluorophenyl)-5-(pyridin-3-yl)-1,2,4-oxadiazole 
• 1120330-81-5 C₂₇H₂₉FN₂O₈ 
• 1120330-75-7 C₂₇H₂₉FN₂O₈ 
• 794554-75-9 C₉H₈ClFN₂O₂ 
• 1429329-91-8 1-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)-1-(pyridin-4-yl)ethanol 
• 330830-97-2 3,5-bis(4-fluorophenyl)-1,2,4-oxadiazole 

Relevant articles and documents

Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses

This article describes the synthesis and antiviral activity evaluation of new substituted 1,2,4-oxadiazoles containing a bicyclic substituent at position 5 of the heterocycle and O-acylated amidoximes as precursors for their synthesis. New compounds were

Cobalt-Catalyzed, Directed Intermolecular C-H Bond Functionalization for Multiheteroatom Heterocycle Synthesis: The Case of Benzotriazine

Transition-metal-catalyzed, directed intermolecular C-H bond functionalization is synthetically useful but heavily underexplored in multiheteroatom heterocycle synthesis. Herein we report a cobalt catalytic method for the formation of a three-nitrogen-bearing benzotriazine scaffold via the coupling of arylhydrazine and oxadiazolone. This synthetic protocol features a low-cost base metal catalyst, a maximum number of heteroatoms built into a heterocycle, a distinct synthetic logic for benzotriazines, a superior step economy, and a broad substrate scope.

Novel 1,2,4-oxadiazole derivatives as selective butyrylcholinesterase inhibitors: Design, synthesis, and biological evaluation

Alzheimer’s disease (AD) is a progressive mental disorder that brings a huge economic burden to the healthcare systems. During this illness, acetylcholine levels in the cholinergic systems gradually diminish, which results in severe memory loss and cognitive impairments. Moreover, Butyrylcholinesterase (BuChE) enzyme participates in cholinergic neurotransmission regulation by playing a prominent role in the latter phase of AD. In this study, based on donepezil, which is an effective acetylcholinesterase (AChE) inhibitor, a series of 1,2,4-oxadiazole compounds were designed, synthesized and their inhibitory activities towards AChE and BuChE enzymes were evaluated. Some structures exhibited a higher selectivity rate towards BuChE in comparison to donepezil. Notably, compound 6n with an IC50 value of 5.07 μM and an SI ratio greater than 19.72 showed the highest potency and selectivity towards BuChE enzyme. The docking result revealed that compound 6n properly fitted the active site pocket of BuChE enzyme, and formed desirable lipophilic interactions and hydrogen bonds. Moreover, according to in silico ADME studies, these compounds have proper potential for being developed as new oral anti-Alzheimer’s agents.